Atrium Therapeutics, Inc. (RNA)
8.26
-0.14
(-1.67%)
USD |
NASDAQ |
Oct 29, 16:00
8.25
-0.01
(-0.12%)
After-Hours: 20:00
Atrium Therapeutics Enterprise Value : -121.23M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -121.23M |
| October 28, 2026 | -118.84M |
| October 27, 2026 | -120.21M |
| October 26, 2026 | -124.82M |
| October 23, 2026 | -122.26M |
| October 22, 2026 | -122.94M |
| October 21, 2026 | -125.68M |
| October 20, 2026 | -126.02M |
| October 19, 2026 | -132.35M |
| October 16, 2026 | -131.32M |
| October 15, 2026 | -128.76M |
| October 14, 2026 | -131.15M |
| October 13, 2026 | -129.96M |
| October 12, 2026 | -122.09M |
| October 09, 2026 | -118.84M |
| October 08, 2026 | -121.23M |
| October 07, 2026 | -126.88M |
| October 06, 2026 | -125.85M |
| October 05, 2026 | -126.19M |
| October 02, 2026 | -128.42M |
| October 01, 2026 | -123.29M |
| September 30, 2026 | -120.89M |
| September 29, 2026 | -118.50M |
| September 28, 2026 | -118.50M |
| September 25, 2026 | -120.72M |
| Date | Value |
|---|---|
| September 24, 2026 | -122.43M |
| September 23, 2026 | -120.04M |
| September 22, 2026 | -104.81M |
| September 21, 2026 | -105.32M |
| September 18, 2026 | -109.43M |
| September 17, 2026 | -98.99M |
| September 16, 2026 | -100.02M |
| September 15, 2026 | -89.93M |
| September 14, 2026 | -87.88M |
| September 11, 2026 | -85.31M |
| September 10, 2026 | -85.48M |
| September 09, 2026 | -82.74M |
| September 08, 2026 | -68.37M |
| September 04, 2026 | -19.79M |
| September 03, 2026 | -12.78M |
| September 02, 2026 | -22.02M |
| September 01, 2026 | -26.98M |
| August 31, 2026 | -34.68M |
| August 28, 2026 | -29.20M |
| August 27, 2026 | -23.39M |
| August 26, 2026 | -25.61M |
| August 25, 2026 | -23.04M |
| August 24, 2026 | -29.54M |
| August 21, 2026 | -36.73M |
| August 20, 2026 | -31.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -58.55M |
| Exicure, Inc. | 4.241M |
| Century Therapeutics, Inc. | 182.55M |
| Absci Corp. | 1.879B |
| Celularity, Inc. | 94.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 3.004M |
| Total Expenses (Quarterly) | 23.19M |
| EPS Diluted (Quarterly) | -1.18 |
| Gross Profit Margin (Quarterly) | 88.58% |
| Profit Margin (Quarterly) | -672.0% |
| Earnings Yield | -55.78% |
| Normalized Earnings Yield | -55.78 |